Bipolar Depression Neurobiology – 2014 ISBD Update

Peter Forster Bipolar Treatment, Psychobiology

Bipolar depression neurobiology is an area that urgently needs more research. The treatment of a depression that follows an energized (hypomanic or manic) state remains one of the most difficult areas in psychiatry. Mark Frye, Chair of the Department of Psychiatry at the Mayo Clinic, gave a presentation on this topic at the 2014 International Society of Biological Society conference that was …

Lithium Benefits for Health – NYT Article

Peter Forster Bipolar Treatment

Does lithium have benefits for health when it is found at small doses in the water? This is the subject of a recent article in the New York Time (september 13th, 2014). The article captured the attention of many readers of this blog and the companion one I write about mood disorders (moodsurfing.com). It was tantalizingly entitled,”Should We All Take a Bit …

Early Lithium Treatment for Bipolar – Better Outcomes?

Peter Forster Bipolar Treatment

Does early lithium treatment for bipolar lead to better outcomes? This is the question that researchers sought to answer by looking at a Danish database of health information. The Danish registry is a set of nearly complete health information on the population of Denmark (hence, studies using this database are more representative of the general population than studies from many …

Lithium Treats Bipolar Depression

admin Bipolar Treatment

In a special symposium on bipolar disorder at the 2014 meeting of the American Psychiatric Association, researcher Mike Bauer reviewed a new meta-analysis that showed lithium not only has significant effects in preventing manias, but also depressions. Mike Bauer is currently the Director and Executive Chair of the Department of Psychiatry and Psychotherapy, and the Physician-in-Chief, at the Psychiatric Hospital …

Lithium versus Quetiapine for Bipolar Disorder

admin Uncategorized

In a recent study comparing the efficacy of lithium and the second-generation antipsychotic quetiapine, the drugs had remarkably similar results. Researcher Andrew Nierenberg et al. presented the results at the 2014 meeting of the American Society of Clinical Psychopharmacology. By the end of the 6-month study period, most patients had improved substantially, but only about a quarter of each group became …